---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-007701"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2022-03-29T23:59:59+00:00"
generated_at: "2026-06-26T15:05:16.976351+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma reports Q4/FY2021 net loss $250.2M; cash $898M; two INDs cleared

## Summary
- Net loss $250.2M in FY2021 vs $204.5M in 2020; non-GAAP net loss $147.9M.
- R&D expense $138.7M in FY2021, down from $182.2M; G&A expense $89.1M vs $46.9M.
- Cash, cash equivalents and marketable securities $898M as of Dec 31, 2021.
- FDA cleared INDs for LYL797 (CAR T targeting ROR1) and LYL132 (TCR targeting NY-ESO-1); initial data from LYL797 trial expected in 2023.
- LYL845 TIL therapy IND on track for H2 2022; LYL331 IND (GSK collaboration) delayed to late 2022/early 2023.

## SEC filing metadata
- accession: 0001628280-22-007701
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2022-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000162828022007701/0001628280-22-007701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000162828022007701/lyel-20220329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-007701
- JSON: https://secwatch.observer/filing/0001628280-22-007701.json
- Plain text: https://secwatch.observer/filing/0001628280-22-007701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.